Lyra Therapeutics Inc 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lyra Therapeutics Inc 's ROA in the fourth quarter of 2025?
Lyra Therapeutics Inc recorded a cumulative net loss of $-29 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -61.3%.

However, within the Healthcare sector 624 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2025 quarter, so far to 4131, from total ROA ranking in the third quarter of 2025 at 4199.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	-18.73 %	-22.03 %	-26.06 %	-41.48 %	-59.19 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-29	-33	-39	-80	-93
Return On Assets (TTM)	-61.3 %	-66.89 %	-74.19 %	-139.59 %	-139.55 %
LYRA's Total Ranking	# 4131	# 4199	# 4558	# 5216	# 4542
Total Assets (TTM) in million	36	44	53	56	44
Seq. Total Assets Change	-17.39 %	-16.86 %	-6.65 %	26.76 %	-20.74 %
Seq. Net Income Change	-	-	-	-	-

LYRA's 5 Years Annual ROA >> Back to LYRA Management Effectiveness >> Compare LYRA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 151
Sector	# 625
Overall	# 4096

Return On Assets Statistics
High	Average	Low
-29.34 %	-61.74 %	-107.47 %
(Dec 31 2020)		(Mar 31 2025)

Financial Statements
Lyra Therapeutics Inc 's Assets	$ 36 million	LYRA's Balance sheet
Lyra Therapeutics Inc 's Income	$ -7 million	Quarterly LYRA's Income Statement
LYRA's Income by Division		See LYRA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-43.9 %	-59.19 %	1.67 %	96.75 %	-31.18 %
Total Assets in million	25	44	109	107	54
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-29	-93	-63	-55	-44
Annual Return On Assets	-116.03 %	-210.3 %	-57.58 %	-51.63 %	-79.96 %

LYRA's 5 Years Annual ROA >> Back to LYRA Management Effectiveness >> Compare LYRA ROA to its Competitors

More Return On Assets Ratios
LYRA's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LYRA's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LYRA's Competitors
Subscribers only: Roa for Lyra Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for LYRA's Customers

You may also want to know
LYRA's Roi	LYRA's Inventory Turnover Ratio	LYRA's Growth Rates	LYRA's Dividend Comparisons
	LYRA's Profitability Ratios	LYRA's Asset Turnover Ratio	LYRA's Dividend Growth
LYRA's Roe	LYRA's Valuation Ratios	LYRA's Financial Strength Ratios	LYRA's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-07-07T12:01:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.